Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel

European Journal of Public Health

Volumn 19, Issue 3, 2009, Pages 254-259

  Chodick, Gabriel ^a,b   Waisbourd Zinman, Orith ^c   Shalev, Varda ^a,b   Kokia, Ehud ^a,b   Rabinovich, Mordechai ^a   Ashkenazi, Shai ^b,c  

^a MACCABI HEALTHCARE SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Cost effectiveness; Immunization; Rotavirus

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; EVIDENCE BASED PRACTICE; GASTROENTERITIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMUNIZATION; ISRAEL; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; VACCINATION; VIRUS INFECTION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; ISRAEL; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SICKNESS IMPACT PROFILE;

EID: 66249115943     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckp005     Document Type: Article

References (32)

1. Pickering L, Snyder J. Gastroenteritis. In: Behrman R, Kliegman R, Arvin A, editors. Nelson textbook of pediatrics, 17th edn. Philadelphia, PA: WB Saunders Company, 1996, 721-4.
2. American Academy of Pediatrics. Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Practice parameters: the management of acute gastroenteritis in young children. Pediatrics 1996;97:424-33.
3. Van Damme P, Van der Wielen M, Ansaldi F, et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis 2006;6:805-12.
4. Parashar U, Hummelman E, Bresee J, et al. Global illness, & deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565-72.
5. World Health Organization. Cost effectiveness of rotavirus vaccines and other interventions for diarrhoeal diseases: meeting report 2006. Weekly Epidemiolog Record 2006;81:350-3.
6. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
7. Gresaro-suan G, Pearl S, Shlezinger A, et al. Hospitalisations for rotavirus gastroenteritis in Israel: A Multicenter Retroospective Study. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20; Chicago, Il, 2007.
8. Galati JC, Harsley S, Richmond P, Carlin JB. The burden of rotavirus-related illness among young children on the Australian health care system. Aust N Z J Public Health 2006;30:416-21.
9. Hsu VP, Abdul Rahman HB, Wong SL, et al. Estimates of the burden of rotavirus disease in Malaysia. J Infect Dis 2005;l92(Suppl. 1):S80-6.
10. Jit M, Edmunds W. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007;16:3971-9.
11. Baltussen R, Taghreed A, Tan-Torres Edejer T, et al. Methods for generalized cost-effectiveness analysis. In: Tan-Torres Edejer T, Baltussen R, Adam T, et al., editors. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World health Organization, 2003, 3-97.
12. Lipscomb J, Weinstein M, Torrance G. Time preference. In: Gold M, Siegel J, Russell L, Weinstein M, editors. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996, 214-46.
13. Central Bureau of Statistics. Israel Statistical Abstract. Jerusalem, 2007. Report No. 58, p. 318.
14. Ginsberg GM, Somekh E. Cost containment analysis of childhood vaccination against varicella in Israel. J Infect 2004;48:119-33.
15. Khuri-Bulos N, Al Khatib M. Importance of rotavirus as a cause of gastroenteritis in Jordan: a hospital based study. Scand J Infect Dis 2006;38:639-44.
16. Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatric Infect Dis J 2006;25:S7-11.
17. Lorgelly P, Joshi D, Iturriza Gomara M, et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008;136:44-55.
18. Vesikari T, Matson D, Dennehy P. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
19. Israel Ministry of Health. Taarif of Medical Services. 2007 (cited 2007; Available from: www.health.gov.il) [Accessed 3 February 2009].
20. Central Bureau of Statistics. Labor Force Survey-2005. 2006 (cited; Available from: www.cbs.gov.il) [Accessed 3 February 2009].
21. O'Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines 2007;6:11-9.
22. Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007;119:684-97.
23. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
24. Stratton K, Durch J, Lawrence RS. Vaccines for the 21st century; A tool for decision making. Washington, DC: National Academy Press, 2000.
25. Ho A, Nelson E, Walker D. Rotavirus vaccination for Hong Kong children; An economic evaluation from the Hong Kong government perspective. Arch Dis Child 2008;92:52-8.
26. Chodick G, Green MS, Heymann AD, et al. The shifting epidemiology of hepatitis A following routine childhood immunization program in Israel. Prev Med 2007;45:386-91.
27. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005;294:202-10.
28. Harris J, Jit M, Cooper D, Edmunds W. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 2007;25:3962-70.
29. Woods P, Gentsch J, Gouvea V, et al. Distribution of serotypes of human rotavirus in different populations. J Ciln Microbiol 1992;30:781-5.
30. Rheingans R, Heylen J, Giaquinto C. Economics of rotavirus gastroenteritis and vaccination in Europe What makes sense? Pediatric Infect Dis J 2006;25:S48-55.
31. Institute of Medicine. Vaccines for the 21st century; A Tool for Decision Making. Washington, DC: National Academy Press, 2000.
32. Ginsber G, Slater P, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 2001;34:92-9.